Thromboprophylaxis for patients with cancer and central venous catheters
- 10 April 2008
- Vol. 112 (11), 2483-2492
- https://doi.org/10.1002/cncr.23479
Abstract
BACKGROUND. Central venous catheter (CVC) placement increases the risk of thrombosis and subsequent death in patients with cancer. The objective of this systematic review was to determine the efficacy and safety of anticoagulation in reducing mortality and thromboembolic events in cancer patients with a CVC. METHODS. The authors searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and ISI the Web of Science databases. They included randomized controlled trials in patients with cancer comparing unfractionated heparin (UFH), low‐molecular‐weight heparin (LMWH), vitamin K antagonists, fondaparinux, or ximelagatran with no intervention, placebo, or each other. The standard methods of the Cochrane Collaboration were used for the analyses. RESULTS. Of 3986 identified citations we included 9 randomized clinical trials, none of which evaluated fondaparinux or ximelagatran. Heparin therapy (UFH or LMWH) was associated with a trend toward a reduction in symptomatic deep venous thrombosis (DVT) (relative risk (RR), 0.43; 95% confidence interval (95% CI), 0.18–1.06), but there was no statistically significant effect on mortality (RR, 0.74; 95% CI, 0.40–1.36), infection (RR, 0.91; 95% CI, 0.36–2.28), major bleeding (RR, 0.68; 95% CI, 0.10–4.78), or thrombocytopenia (RR, 0.85; 95% CI, 0.49–1.46). The effect of warfarin on symptomatic DVT also was not statistically significant (RR, 0.62; 95% CI, 0.30–1.27). CONCLUSIONS. The balance of benefits and downsides of thromboprophylaxis in cancer patients with CVC are uncertain. Clinicians together with their patients must weigh these factors carefully when making decisions regarding thromboprophylaxis. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 32 references indexed in Scilit:
- Low‐dose warfarin for the prevention of central line‐associated thromboses in children with malignancies—a randomized, controlled studyActa Paediatrica, 2006
- Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trialAnnals of Oncology, 2005
- Randomized Trial of Prevention of Catheter-Related Bloodstream Infection by Continuous Infusion of Low-Dose Unfractionated Heparin in Patients With Hematologic and Oncologic DiseaseJournal of Clinical Oncology, 2005
- Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With CancerJournal of Clinical Oncology, 2005
- Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer PatientsJournal of Clinical Oncology, 2005
- Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over timeJournal of Clinical Epidemiology, 2004
- Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological diseaseThrombosis and Haemostasis, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood, 2002
- Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosisInternal Medicine Journal, 2002